137 related articles for article (PubMed ID: 37768120)
1. [Surgery of peritoneal surface malignancies - surgical cytoreduction and hyperthermic intraperitoneal chemotherapy].
Huszty G; Bihari L; Gráf L; Szijártó A; Máté S
Magy Onkol; 2023 Sep; 67(3):247-258. PubMed ID: 37768120
[TBL] [Abstract][Full Text] [Related]
2. Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.
Klos D; Riško J; Stašek M; Loveček M; Hanuliak J; Skalický P; Lemstrová R; Mohelníková BD; Študentová H; Neoral Č; Melichar B
Cas Lek Cesk; 2018 Dec; 157(8):419-428. PubMed ID: 30754979
[TBL] [Abstract][Full Text] [Related]
3. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan.
Kitai T
Surg Today; 2021 Jul; 51(7):1085-1098. PubMed ID: 33185798
[TBL] [Abstract][Full Text] [Related]
4. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661
[TBL] [Abstract][Full Text] [Related]
5. The robotic future of minimally invasive cytoreduction and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Ortega J; Orfanelli T; Levine E; Konstantinidis IT
Chin Clin Oncol; 2023 Apr; 12(2):16. PubMed ID: 36946185
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
7. [Clinical practice guideline on peritoneal carcinomatosis treatment using surgical cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy].
Kavanagh M; Ouellet JF;
Bull Cancer; 2006 Sep; 93(9):867-74. PubMed ID: 16980229
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
Sugarbaker PH
Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy.
Pletcher E; Gleeson E; Labow D
Surg Clin North Am; 2020 Jun; 100(3):589-613. PubMed ID: 32402303
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal metastases: challenges for the surgeon.
Baratti D; Kusamura S; Guaglio M; Deraco M
Minerva Chir; 2015 Jun; 70(3):195-215. PubMed ID: 25752673
[TBL] [Abstract][Full Text] [Related]
11. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
[TBL] [Abstract][Full Text] [Related]
12. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.
Golse N; Bakrin N; Passot G; Mohamed F; Vaudoyer D; Gilly FN; Glehen O; Cotte E
J Surg Oncol; 2012 Aug; 106(2):197-203. PubMed ID: 22331814
[TBL] [Abstract][Full Text] [Related]
13. The many faces of intraperitoneal chemotherapy.
Abdel Mageed H; Van Der Speeten K; Sugarbaker P
Surg Oncol; 2022 Mar; 40():101676. PubMed ID: 34875459
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand?
Witmer HDD; Dhiman A; Turaga KK
Cancer; 2023 Feb; 129(4):495-502. PubMed ID: 36527271
[TBL] [Abstract][Full Text] [Related]
16. Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review.
Eftimie MA; Potlog G; Alexandrescu ST
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837456
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
18. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer].
Gronau F; Jara M; Feldbrügge L; Wolf V; Oeff A; Rau B
Chirurg; 2021 Jun; 92(6):522-527. PubMed ID: 33620502
[TBL] [Abstract][Full Text] [Related]
19. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.
Fung X; Li IC; Chandrakumaran K; Cecil T; Dayal S; Tzivanakis A; Moran B; Mohamed F
Eur J Surg Oncol; 2022 Jul; 48(7):1614-1618. PubMed ID: 35168851
[TBL] [Abstract][Full Text] [Related]
20. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
